CapyFin

Loading...

CapyFin Real-time Earnings Reports.

X LinkedIn

Products

Earnings

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

Bio-Techne

🇺🇸 NASDAQ:TECH

View Company

Overview Earnings Dividends

Feb 01, 2024

•

Dec 31, 2023

Bio-Techne Q2 2024 Earnings Report

Bio-Techne's Q2 2024 earnings were released, revealing a slight revenue increase and mixed segment performance amid challenging macroeconomic conditions.

Key Takeaways

Bio-Techne reported flat revenue growth in the second quarter of fiscal year 2024, with organic revenue declining by 2%. GAAP EPS was $0.17, while adjusted EPS was $0.40. The company faced headwinds from BioPharma macroeconomic conditions but saw strength in the academic end market and growth in instrument consumables.

Organic revenue declined by 2% to $272.6 million.

GAAP EPS was $0.17, and adjusted EPS was $0.40.

Instrument consumables grew by 20%, offsetting BioPharma headwinds.

Cash flow from operations increased by 18% to $142.5 million.

Total Revenue

$273M

Previous year: $272M

+0.4%

EPS

$0.4

Previous year: $0.47

-14.9%

Organic sales growth

-2%

Previous year: 4%

-150.0%

Gross Profit

$177M

Previous year: $183M

-3.7%

Cash and Equivalents

$130M

Previous year: $165M

-21.0%

Free Cash Flow

$68.3M

Previous year: $58.3M

+17.1%

Total Assets

$2.73B

Previous year: $2.36B

+15.5%

Bio-Techne

Bio-Techne Revenue by Segment

Revenue by Segment

Protein Sciences Revenue

CapyFin.com

Diagnostics & Spatial Bio Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Bio-Techne